Fake Ozempic Flooding U.S. Supply Chain: FDA Issues Urgent Warning

June 26, 2023 : The United States Food and Drug Administration (FDA) has warned healthcare professionals and consumers about counterfeit Ozempic injections circulating in the U.S. drug supply chain. Ozempic, a brand-name medication containing semaglutide, is prescribed for adults with type 2 diabetes to help control blood sugar levels.

The Scope of the Problem

The FDA identified counterfeit Ozempic in the market with lot number NAR0074 and serial number 430834149057. These fake products come in 1mg pre-filled pens and appear strikingly similar to the authentic medication. However, the agency emphasizes that the needles in these counterfeit versions are unsterile and pose a significant risk of infection. Additionally, the contents of the counterfeit pens remain unknown, raising concerns about potential adverse effects and ineffectiveness in treating diabetes.

Potential Risks and Precautions

Individuals using counterfeit Ozempic face several potential health risks, including:

• Infections: The unsterile needles in the counterfeit pens increase the risk of contracting serious infections at the injection site or even in the bloodstream.
• Adverse reactions: The unknown contents of the counterfeit pens raise concerns about potential allergic reactions or other unpredictable side effects.
• Ineffective treatment: Counterfeit Ozempic may not contain the correct semaglutide dosage or any medication at all, potentially jeopardizing blood sugar control and diabetes management.

The FDA urges healthcare professionals and patients to take the following precautions:

• Verify product authenticity: Carefully check the lot and serial numbers on Ozempic pens to ensure they match the legitimate product.
• Purchase from authorized sources: Only obtain Ozempic from licensed pharmacies or healthcare providers to guarantee its authenticity.
• Report suspected counterfeits: Immediately report any suspected counterfeit Ozempic to the FDA using their online reporting system or by calling 1-800-FDA-1088.

Protecting Patient Safety

The FDA is actively investigating the source of the counterfeit Ozempic and taking steps to remove these products from the market. However, this incident highlights the importance of vigilance and awareness among healthcare professionals and patients. By following the FDA’s recommendations and reporting any suspected counterfeits, individuals can help ensure the safety and efficacy of their medications.